Category Archives: MS Treatment

The Changing View of Immunopathology in MS Treatment Presented by: Edward J. Fox, MD, PhD. By: TheFranceFoundation … Continue reading →

Principles of MS Treatment Presented by: Bruce Cree, MD, PhD. By: TheFranceFoundation … Continue reading →

By Levi Ismail Published: Saturday, May 18, 2013, 7:12 pm Related Content MASON CITY, IA -Its an opportunity to raise awareness for a disease many of us are still learning about. Walk MS brings together people of all walks of life for the common goal of curing the nervous system disease. For organizers, the main goal is to raise the $22,000 for research of a cure, but others say, supporting those affected by MS can make all the difference in finding a cure. An event like this makes people go What are all those folks in the orange shirts walking for? Oh, its the MS walk, what is MS? It just kind of raises it up to the forefront of discussion on what MS is and lets people understand the symptoms. Also, how people are afflicted with multiple sclerosis, said Joe Malone of Mason City. The walk which began at North Iowa Community College, spanned two miles and gave an opportunity for participants to meet and greet others affected by the disease. Since beginning the fundraiser back in 1988, the Walk MS event has earned more than $10 million dollars to help support people living with MS. For Joe, while … Continue reading →

Public release date: 17-May-2013 [ | E-mail | Share ] Contact: Charles Casey charles.casey@ucdmc.ucdavis.edu 916-734-9048 University of California - Davis Health System (SACRAMENTO, Calif.) Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved medications against MS. The findings of the research study, published online today in the journal EMBO Molecular Medicine could have therapeutic applications for MS as well as cerebral palsy and leukodystrophies, all disorders associated with loss of white matter, which is the brain tissue that carries information between nerve cells in the brain and the spinal cord. The target, a protein referred to as mitochondrial translocator protein (TSPO), had been previously identified but not linked to MS, an autoimmune disease that strips the protective fatty coating off nerve fibers of the brain and spinal cord. The mitrochronical TSPO is located on the outer surface of mitochondria, cellular structures that supply energy to the cells. Damage to the fatty coating, or myelin, slows the transmission of the nerve signals that enable body movement as well as sensory and cognitive functioning. The scientists identified mitochondrial … Continue reading →

May 17, 2013 Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved medications against MS. The findings of the research study, published online today in the journal EMBO Molecular Medicine could have therapeutic applications for MS as well as cerebral palsy and leukodystrophies, all disorders associated with loss of white matter, which is the brain tissue that carries information between nerve cells in the brain and the spinal cord. The target, a protein referred to as mitochondrial translocator protein (TSPO), had been previously identified but not linked to MS, an autoimmune disease that strips the protective fatty coating off nerve fibers of the brain and spinal cord. The mitrochronical TSPO is located on the outer surface of mitochondria, cellular structures that supply energy to the cells. Damage to the fatty coating, or myelin, slows the transmission of the nerve signals that enable body movement as well as sensory and cognitive functioning. The scientists identified mitochondrial TSPO as a potential therapeutic target when mice that had symptoms of MS improved after being treated with the anti-anxiety drug … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/n5dsmq/pharmapoint) has announced the addition of the "PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022" report to their offering. PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFN) agents: Bayer's Betaseron/Betaferon (IFN-1b), Biogen's Avonex (IFN-1a) and Merck's Rebif (IFN-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace. The US is the largest MS market due to the high prevalence of the disease and comparatively high MS drug prices.During the forecast period, … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/njkqmx/gilenya_multiple) has announced the addition of the "Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022" report to their offering. Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFN) agents: Bayer's Betaseron/Betaferon (IFN-1b), Biogen's Avonex (IFN-1a) and Merck's Rebif (IFN-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace. Novartis' Gilenya (fingolimod; FTY720) was the first FDA-approved, orally-administered DMT available for the treatment of MS. Gilenya is a synthetic analogue of the fungus Isaria sinclarii that was … Continue reading →

Arrest warrants have been issued against Zaibunissa Kazi and Sharif Parkar who have been convicted for their role in the 1993 Mumbai blasts case. The two, who were supposed to surrender before court today, failed to do so thus prompting the warrants. Mr Parkar is presently admitted to Prince Aly Khan Hospital in Byculla, Mumbai where he is due to undergo angioplasty. The 71-year-old Ms Kazi is reportedly undergoing medical treatment. Ms Kazi was ordered in Mrach by the Supreme Court to serve five years for her role in the 1993 serial bombings in Mumbai, one of the worst terror attacks in India. In April, her appeal to be given a month's reprieve before being sent to jail was granted by a Mumbai court on humanitarian and health grounds. Yesterday, celebrity actor Sanjay Dutt, also convicted in the Mumbai blasts case surrendered at a special court in Mumbai and returned to jail. He has already spent part of his five-year-sentence and has to serve 42 months more. Originally posted here: 1993 Mumbai blast case: Arrest warrant against Zaibunissa Kazi and Sharif Parkar for failing to surrender … Continue reading →

FREDERICTON - A fund set up to help multiple sclerosis patients in New Brunswick pay for so-called liberation therapy will continue, Finance Minister Blaine Higgs said Thursday, despite waning interest and questions over the efficacy of the unproven treatment. Higgs said the government decided to continue offering public money to people seeking the treatment outside Canada to fulfil a campaign promise, even though a number of studies have cast doubt about the procedure. "We want the medical professionals to help advise on that and to help us go forward on that," Higgs said. The government has budgeted $75,000 for the fund this year, on top of the $400,000 it set aside in the first two years of the program. Applicants can get $2,500 each if a community group raises matching funds for the procedure, which can cost more than $10,000. But interest in the fund has fallen short of expectations. Only $210,000 has been spent so far, Higgs said, with 84 people having received the money to pay for the treatment. Jessesar Mitchell, a spokeswoman for the MS Society's Atlantic division, said while the organization supports anyone's decision to seek the treatment, it may be wiser to spend the money … Continue reading →

Tony Abbott's commitment to working women is under fire after the coalition declined a request from a Labor backbencher who needed to care for her sick child. Michelle Rowland, the MP for Greenway in Sydney's west, had sought a "pair" from the coalition so she could get back home on Thursday night to be with her ill 14-month-old daughter Octavia. But opposition whip Warren Entsch denied Ms Rowland's request on the basis that the wording of her application suggested no sense of urgency and there was "no attempt" to provide more information. The system of pairs allows the coalition and government benches to ensure neither side gets an advantage in voting in the parliament when a member is absent. Mr Entsch later explained his view further to ABC radio, saying he believed Ms Rowland should have been with her child in any case. "It seems rather bizarre to be putting in a request on Monday or Tuesday asking for leave on Thursday night because her child is unwell. If it's unwell now, she should be with it," he said. However, the rejection caused uproar in Labor ranks. Families Minister Jenny Macklin told parliament Mr Entsch should be sacked. "He is … Continue reading →